Description

Retatrutide 5mg + Cagrilintide 20mg × 10 vials

A dual-compound metabolic research blend studied for obesity-related models, appetite-regulation pathways, glucose metabolism, glucagon/GLP-1/GIP receptor signaling, amylin receptor pathways, body-weight regulation, liver-fat metabolism, and broader metabolic-disease research protocols.

Product Overview

Compound: Retatrutide + Cagrilintide
Strength: Retatrutide 5 mg + Cagrilintide 20 mg per vial
Injection type: Research protocol dependent
Frequency: Research protocol dependent

Reconstitution

Amount in vial: 25 mg total
Retatrutide: 5 mg
Cagrilintide: 20 mg
BAC water: 2 mL
Amount per unit: 125 mcg total per unit

Research Dose

Protocol dependent.

Notes

Retatrutide is described as an investigational triple receptor agonist studied for activity at GIP, GLP-1, and glucagon receptors. These pathways are researched in relation to appetite regulation, glucose metabolism, energy expenditure, liver-fat metabolism, insulin-sensitivity mechanisms, and body-weight regulation.

Cagrilintide is described as a long-acting amylin analogue studied for appetite regulation, satiety signaling, gastric-emptying pathways, glucose-related mechanisms, and body-weight management research models.

This blend is primarily associated with metabolic, obesity-related, appetite-regulation, and body-composition research. It should not be treated as a standard wellness, cosmetic, or consumer weight-loss product.

Most available evidence comes from clinical research programs and investigational drug studies. No standard consumer dosing protocol should be assumed.

Use only within appropriate research or professional guidance frameworks.